Belinostat is a histone deacetylase (HDAC) inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. This category offers a comprehensive range of reference… Read more



















Belinostat is a histone deacetylase (HDAC) inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. This category offers a comprehensive range of reference standards for Belinostat, including the active pharmaceutical ingredient, related process-related impurities, and metabolic degradation products. Pharmaceutical laboratories utilize these materials for rigorous analytical testing, ensuring accurate impurity profiling and method validation throughout the drug development lifecycle. To support precise quantification in complex biological matrices, the collection includes stable isotope labelled compounds, such as deuterated analogues, which serve as essential internal standards in mass spectrometry workflows. Researchers rely on these well-characterized materials for consistent quality control and to support compliance with regulatory standards during the manufacturing and analysis of this therapeutic agent.